STOCK TITAN

[Form 4] Tecogen Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 – Tecogen Inc. (TGEN)

  • Reporting person: Susan B. Hirsch, Director.
  • Transaction date: 07/24/2025.
  • Instrument: Stock Option (right to buy) covering 25,000 common shares at an exercise price of $8.35.
  • Vesting: 25 % per year; first exercisable 07/24/2026; expiration 07/24/2035.
  • Post-transaction holdings: Hirsch now directly holds 150,000 derivative securities (options).

No non-derivative (common stock) transactions were reported. The filing reflects a routine option grant to a board member and does not disclose cash compensation, sale activity, or changes in direct share ownership.

Modulo 4 – Tecogen Inc. (TGEN)

  • Persona che segnala: Susan B. Hirsch, Direttrice.
  • Data della transazione: 24/07/2025.
  • Strumento: Opzione su azioni (diritto di acquisto) per 25.000 azioni ordinarie a un prezzo di esercizio di $8,35.
  • Consolidamento: 25% all'anno; prima esercitabilità il 24/07/2026; scadenza il 24/07/2035.
  • Detenzioni dopo la transazione: Hirsch detiene ora direttamente 150.000 strumenti derivati (opzioni).

Non sono state segnalate transazioni su azioni ordinarie non derivate. La comunicazione riflette una concessione ordinaria di opzioni a un membro del consiglio e non indica compensi in denaro, attività di vendita o variazioni nella proprietà diretta delle azioni.

Formulario 4 – Tecogen Inc. (TGEN)

  • Persona que reporta: Susan B. Hirsch, Directora.
  • Fecha de la transacción: 24/07/2025.
  • Instrumento: Opción sobre acciones (derecho a comprar) que cubre 25,000 acciones comunes a un precio de ejercicio de $8.35.
  • Consolidación: 25% por año; primera ejercitabilidad el 24/07/2026; vencimiento el 24/07/2035.
  • Posiciones tras la transacción: Hirsch ahora posee directamente 150,000 valores derivados (opciones).

No se reportaron transacciones con acciones comunes no derivadas. La presentación refleja una concesión rutinaria de opciones a un miembro del consejo y no revela compensación en efectivo, actividad de venta ni cambios en la propiedad directa de acciones.

양식 4 – Tecogen Inc. (TGEN)

  • 보고자: Susan B. Hirsch, 이사.
  • 거래일: 2025년 7월 24일.
  • 금융상품: 보통주 25,000주를 매수할 권리가 있는 스톡 옵션, 행사가격 $8.35.
  • 권리 취득 조건: 연 25%; 최초 행사 가능일 2026년 7월 24일; 만료일 2035년 7월 24일.
  • 거래 후 보유: Hirsch는 현재 직접 150,000개의 파생 증권(옵션)을 보유 중.

비파생 보통주 거래는 보고되지 않았습니다. 이번 신고는 이사회 멤버에게 정기적으로 부여된 옵션으로 현금 보상, 매도 활동 또는 직접 주식 소유 변화는 포함하지 않습니다.

Formulaire 4 – Tecogen Inc. (TGEN)

  • Personne déclarant: Susan B. Hirsch, Directrice.
  • Date de la transaction: 24/07/2025.
  • Instrument: Option d'achat portant sur 25 000 actions ordinaires au prix d'exercice de 8,35 $.
  • Acquisition des droits: 25 % par an ; première possibilité d'exercice le 24/07/2026 ; expiration le 24/07/2035.
  • Positions après la transaction: Hirsch détient désormais directement 150 000 titres dérivés (options).

Aucune transaction sur actions ordinaires non dérivées n'a été signalée. Le dépôt reflète une attribution d'options de routine à un membre du conseil d'administration et ne révèle ni rémunération en espèces, ni activité de vente, ni changement dans la détention directe d'actions.

Formular 4 – Tecogen Inc. (TGEN)

  • Meldender: Susan B. Hirsch, Direktorin.
  • Transaktionsdatum: 24.07.2025.
  • Instrument: Aktienoption (Kaufrecht) für 25.000 Stammaktien zu einem Ausübungspreis von 8,35 $.
  • Vesting: 25 % pro Jahr; erste Ausübung möglich ab 24.07.2026; Ablauf am 24.07.2035.
  • Bestände nach der Transaktion: Hirsch hält nun direkt 150.000 derivative Wertpapiere (Optionen).

Es wurden keine nicht-derivativen (Stammaktien-)Transaktionen gemeldet. Die Meldung zeigt eine routinemäßige Optionszuteilung an ein Vorstandsmitglied und enthält keine Angaben zu Barvergütungen, Verkaufsaktivitäten oder Änderungen des direkten Aktienbesitzes.

Positive
  • Director receives additional long-dated options, signaling ongoing commitment and potential future alignment with shareholder value.
Negative
  • None.

Insights

TL;DR: Routine option grant; limited impact on valuation.

The filing records a standard director option award of 25 k shares at $8.35. It increases Hirsch’s derivative exposure to 150 k options, reinforcing alignment with shareholder interests but does not involve open-market buying or selling of common stock. No immediate dilution occurs because options are long-dated and vest over four years. Given Tecogen’s small-cap profile, the size is modest and unlikely to alter float, earnings, or insider-sentiment metrics materially. I view the disclosure as administratively neutral.

Modulo 4 – Tecogen Inc. (TGEN)

  • Persona che segnala: Susan B. Hirsch, Direttrice.
  • Data della transazione: 24/07/2025.
  • Strumento: Opzione su azioni (diritto di acquisto) per 25.000 azioni ordinarie a un prezzo di esercizio di $8,35.
  • Consolidamento: 25% all'anno; prima esercitabilità il 24/07/2026; scadenza il 24/07/2035.
  • Detenzioni dopo la transazione: Hirsch detiene ora direttamente 150.000 strumenti derivati (opzioni).

Non sono state segnalate transazioni su azioni ordinarie non derivate. La comunicazione riflette una concessione ordinaria di opzioni a un membro del consiglio e non indica compensi in denaro, attività di vendita o variazioni nella proprietà diretta delle azioni.

Formulario 4 – Tecogen Inc. (TGEN)

  • Persona que reporta: Susan B. Hirsch, Directora.
  • Fecha de la transacción: 24/07/2025.
  • Instrumento: Opción sobre acciones (derecho a comprar) que cubre 25,000 acciones comunes a un precio de ejercicio de $8.35.
  • Consolidación: 25% por año; primera ejercitabilidad el 24/07/2026; vencimiento el 24/07/2035.
  • Posiciones tras la transacción: Hirsch ahora posee directamente 150,000 valores derivados (opciones).

No se reportaron transacciones con acciones comunes no derivadas. La presentación refleja una concesión rutinaria de opciones a un miembro del consejo y no revela compensación en efectivo, actividad de venta ni cambios en la propiedad directa de acciones.

양식 4 – Tecogen Inc. (TGEN)

  • 보고자: Susan B. Hirsch, 이사.
  • 거래일: 2025년 7월 24일.
  • 금융상품: 보통주 25,000주를 매수할 권리가 있는 스톡 옵션, 행사가격 $8.35.
  • 권리 취득 조건: 연 25%; 최초 행사 가능일 2026년 7월 24일; 만료일 2035년 7월 24일.
  • 거래 후 보유: Hirsch는 현재 직접 150,000개의 파생 증권(옵션)을 보유 중.

비파생 보통주 거래는 보고되지 않았습니다. 이번 신고는 이사회 멤버에게 정기적으로 부여된 옵션으로 현금 보상, 매도 활동 또는 직접 주식 소유 변화는 포함하지 않습니다.

Formulaire 4 – Tecogen Inc. (TGEN)

  • Personne déclarant: Susan B. Hirsch, Directrice.
  • Date de la transaction: 24/07/2025.
  • Instrument: Option d'achat portant sur 25 000 actions ordinaires au prix d'exercice de 8,35 $.
  • Acquisition des droits: 25 % par an ; première possibilité d'exercice le 24/07/2026 ; expiration le 24/07/2035.
  • Positions après la transaction: Hirsch détient désormais directement 150 000 titres dérivés (options).

Aucune transaction sur actions ordinaires non dérivées n'a été signalée. Le dépôt reflète une attribution d'options de routine à un membre du conseil d'administration et ne révèle ni rémunération en espèces, ni activité de vente, ni changement dans la détention directe d'actions.

Formular 4 – Tecogen Inc. (TGEN)

  • Meldender: Susan B. Hirsch, Direktorin.
  • Transaktionsdatum: 24.07.2025.
  • Instrument: Aktienoption (Kaufrecht) für 25.000 Stammaktien zu einem Ausübungspreis von 8,35 $.
  • Vesting: 25 % pro Jahr; erste Ausübung möglich ab 24.07.2026; Ablauf am 24.07.2035.
  • Bestände nach der Transaktion: Hirsch hält nun direkt 150.000 derivative Wertpapiere (Optionen).

Es wurden keine nicht-derivativen (Stammaktien-)Transaktionen gemeldet. Die Meldung zeigt eine routinemäßige Optionszuteilung an ein Vorstandsmitglied und enthält keine Angaben zu Barvergütungen, Verkaufsaktivitäten oder Änderungen des direkten Aktienbesitzes.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Hirsch Susan B

(Last) (First) (Middle)
280 OLD SOMERSET ROAD

(Street)
WATCHUNG NJ 07069

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TECOGEN INC. [ TGEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $8.35 07/24/2025 A 25,000 07/24/2026(1) 07/24/2035 Common Stock 25,000 $8.35 150,000 D
Explanation of Responses:
1. Vests 25% per year
Remarks:
/s/ Susan B. Hirsch 07/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Tecogen (TGEN) disclose in the July 2025 Form 4?

Director Susan B. Hirsch was granted 25,000 stock options at an exercise price of $8.35 on 07/24/2025.

How many Tecogen options does Susan B. Hirsch own after the transaction?

She holds 150,000 derivative securities (stock options) directly.

When can the newly granted Tecogen options be exercised?

They begin vesting 25 % per year and are first exercisable on 07/24/2026.

Do the Form 4 filings indicate any Tecogen stock sales by the director?

No. The filing reports only an option grant; no shares were sold or purchased on the open market.

What is the expiration date of the Tecogen director’s new options?

The options expire on 07/24/2035.
Tecogen

NYSE:TGEN

TGEN Rankings

TGEN Latest News

TGEN Latest SEC Filings

TGEN Stock Data

251.23M
16.70M
47.24%
0.04%
Electrical Equipment & Parts
Air-cond & Warm Air Heatg Equip & Comm & Indl Refrig Equip
Link
United States
NORTH BILLERICA